About SpectraCure
SpectraCure is a company based in Lund (Sweden) founded in 2003. SpectraCure offers products and services including IDOSE Platform and Laser Unit. SpectraCure operates in a competitive market with competitors including PhotoPharmics, CranioVation, Lumeda, Adgero Biopharma and Photolitec, among others.
- Headquarter Lund, Sweden
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website spectracure.com
- Social LinkedIn X Facebook
- Legal Name Spectracure Ab
- Net Profit-$6.09 M (USD)-143.78as on Dec 31, 2025
- EBITDA-$2.63 M (USD)-10.84as on Dec 31, 2025
- Latest Funding Round$336.21K (USD), Grant
Sep 2020
- Investors
Products & Services of SpectraCure
SpectraCure offers a comprehensive portfolio of products and services, including IDOSE Platform and Laser Unit.
Software for planning precise doses in photodynamic therapy treatments
Device that performs photodynamic therapy for prostate cancer
Funding Insights of SpectraCure
- Total Rounds 1
- Last Round Grant — $336,205
- First Round $336,205
(Sep 2020)
- Investors Count 1
All 1 funding rounds of SpectraCure with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Sep 2020 | $336,205 | Grant | – | – |
1 investors in total: 1 institutional.
Investors in SpectraCure
SpectraCure has secured backing from 1 investor, including institutional investors. Prominent investors backing the company include European Union.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Government entites focused on freedom, democracy, equality and the rule of law, promoting peace and stability | 1958 | europa.eu | Brussels, Belgium |
Investor details for SpectraCure
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
IPO & Listings of SpectraCure
SpectraCure is a publicly listed company on the OMXSTO with ticker symbol SPEC in Sweden, operating in the Electronic technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date01 Jul 2015
- Listed onOMXSTO: SPEC
- Listed entitySpectraCure AB
- Exchange sectorElectronic technology
- ISINSE0007158118
- Share price0.02 SEK (-3.01% on the day) · 2026-10-09
- Market capitalisation23,680,589.00 SEK
- EPS (diluted, trailing year)-0.10 SEK
- Volume (last session)5,438,662
Financials of SpectraCure
| Year | Revenue | Net income | EBITDA |
|---|---|---|---|
| 2025 | – | -56.1M SEK | -24.2M SEK |
| 2024 | – | -23.0M SEK | -21.9M SEK |
| 2023 | – | -20.4M SEK | -21.4M SEK |
| 2022 | – | -25.4M SEK | -25.7M SEK |
| 2021 | – | -23.3M SEK | -26.4M SEK |
Detailed financial statements for SpectraCure
Statement rows, ratios, five-year trends and downloadable financials of the group companies require an active premium plan.
- Statement rows
- Financial ratios
- Five-year trends
- Downloads
Verified entity values are shown only after access is granted.
Timeline of SpectraCure
3 dated milestones of SpectraCure across 17 years, from founding to its latest funding, stage changes and deals.
- Founded SpectraCure is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $336K.
Competitors of SpectraCure
SpectraCure operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as PhotoPharmics, CranioVation, Lumeda, Adgero Biopharma and Photolitec, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| photopharmics.com | 2011 | American Fork, United States | $43.44M | – | Non-invasive phototherapy for Parkinson's disease is developed. | |
| craniovation.com | 2017 | Rochester, United States | $7.61M | – | Minimally invasive devices for brain tumor treatment are provided. | |
| lumedainc.com | 2020 | Rocky Hill, United States | $5.34M | 10 | Photodynamic therapy device for lung cancer treatment is developed. | |
| adgerobiopharm.com | 2012 | Princeton, United States | $5.52M | – | Photodynamic therapy for cutaneous metastatic breast cancer is developed. | |
| photolitec.org | 2010 | Buffalo, United States | $5M | – | Supplies photosensitizing compounds for tumor imaging and photodynamic cancer therapy. | |
| illumimedical.com | 2023 | Nagoya, Japan | $2.26M | – | Photodynamic therapy devices for cancer treatment are developed. | |
| impactbiotech.com | 2022 | Ness Ziona, Israel | – | – | Developer of a drug delivery platform for the treatment of solid tumors | |
| illumacell.com | 2008 | Waterloo, Canada | – | – | Provider of medical light technology for photodynamic therapy cancer treatment |
Detailed competitors of SpectraCure
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of SpectraCure
Websites that share an audience with SpectraCure (spectracure.com).
Websites whose visitors overlap most with SpectraCure. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| youtube.com | 100% | 30.4B | #2 | View details |
Latest news on Spectracure
Complete news archive for SpectraCure
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Similar companies to SpectraCure
10 companies that operate in the same segment as SpectraCure (Oncology), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
mRNA-based therapeutics for diseases including cancer and infections are developed. | 2010 | Cambridge, Massachusetts, United States | USD 2.78 B | USD 1.94 B | 5,800 | |
Novel biopharmaceutical medicines are developed for unmet medical needs. | 2003 | Dublin, Ireland | USD 265 M | USD 4.27 B | 2,800 | |
Digital sequencing technology for cancer detection is developed. | 2012 | Redwood City, California, United States | USD 557.5 M | USD 982.02 M | 2,020 | |
Circulating tumor DNA is screened for early cancer detection. | 2016 | Menlo Park, California, United States | USD 3.22 B | USD 147.17 M | 1,000 | |
Radiopharmaceuticals for oncology diagnostics and therapies are developed and marketed. | 2002 | Saint-genis-pouilly, Ain, France | USD 56.13 M | USD 235.08 M | – | |
Developer of small molecule drugs for the treatment of cancer and inflammatory disease | 2008 | Natick, Massachusetts, United States | USD 98.4 M | USD 146.07 M | 279 | |
Small molecule therapeutics are developed for cancer and rare diseases. | 2017 | New York, New York, United States | USD 229.6 M | – | – | |
Small-molecule drugs for cancer treatment are developed via Degronimid platform. | 2016 | Cambridge, Massachusetts, United States | USD 223 M | USD 35.95 M | 110 | |
Developer of drugs based on T-Cell receptor technology for the treatment of cancer | 2008 | Abingdon, Oxfordshire, United Kingdom | USD 601.28 M | USD 400.95 M | 493 | |
Antibody-based drugs are developed for autoimmune diseases and cancer treatment. | 2008 | Ghent, East Flanders, Belgium | USD 61.9 M | USD 1.41 B | 355 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about SpectraCure
SpectraCure was founded in 2003 and raised its 1st funding round 17 years after it was founded.
SpectraCure is headquartered in Lund, Sweden.
SpectraCure is developing an interstitial photodynamic therapy for solid tumors (prostate and pancreas, as well as ENT). The treatment involves the administration of a photosensitizing drug and a non-thermal laser light under the management of a new dosimetry approach. They have proprietary software, iDOSE, for safe interstitial PDT treatment. iDOSE allows for 3D image-based treatment planning using advanced dose-planning tools to control light exposure.
SpectraCure's top competitors include PhotoPharmics, ImPact Biotech and Adgero Biopharma.
SpectraCure offers IDOSE Platform and Laser Unit.
Yes, SpectraCure is publicly traded on OMXSTO under the ticker symbol SPEC.
SpectraCure has 1 investor. Key investors include European Union.
SpectraCure operates through Spectracure Ab (Publ).